Mastocytosis demystified

2.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

doi:10.1038/s41375-022-01613-1

.

3.

Theoharides

TC

,

Valent

P

,

Akin

C.

Mast cells, mastocytosis, and related disorders

.

N Engl J Med

.

2015

;

373

(

2

):

163

-

172

.

doi:10.1056/NEJMra1409760

.

4.

Mesa

RA

,

Sullivan

EM

,

Dubinski

D

, et al.

Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM Patient Survey

.

Cancer

.

2022

;

128

(

20

):

3691

-

3699

.

doi:10.1002/cncr.34420

.

5.

Valent

P

,

Akin

C

,

Hartmann

K

, et al.

Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal

.

HemaSphere

.

2021

;

5

(

11

):

e646

.

doi:10.1097/hs9.0000000000000646

.

6.

Lim

K-H

,

Tefferi

A

,

Lasho

T-L

, et al.

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

.

Blood

.

2009

;

113

(

23

):

5727

-

5736

.

doi:10.1182/blood-2009-02-205237

.

7.

Sperr

WR

,

Kundi

M

,

Alvarez-Twose

I

, et al.

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

.

Lancet Haematol

.

2019

;

6

(

12

):

e638

-

e649

.

doi:10.1016/s2352-3026(19)30166-8

.

8.

Schwaab

J

,

Schnittger

S

,

Sotlar

K

, et al.

Comprehensive mutational profiling in advanced systemic mastocytosis

.

Blood

.

2013

;

122

(

14

):

2460

-

2466

.

doi:10.1182/blood-2013-04-496448

.

9.

Jawhar

M

,

Schwaab

J

,

Schnittger

S

, et al.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis

.

Leukemia

.

2016

;

30

(

1

):

136

-

143

.

doi:10.1038/leu.2015.284

.

10.

Jawhar

M

,

Schwaab

J

,

Meggendorfer

M

, et al.

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm

.

Haematologica

.

2017

;

102

(

6

):

1035

-

1043

.

doi:10.3324/haematol.2017.163964

.

11.

Pardanani

A

,

Shah

S

,

Mannelli

F

, et al.

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models

.

Blood Adv

.

2018

;

2

(

21

):

2964

-

2972

.

doi:10.1182/bloodadvances.2018026245

.

12.

Jawhar

M

,

Schwaab

J

,

Álvarez-Twose

I

, et al.

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

.

J Clin Oncol

.

2019

;

37

(

31

):

2846

-

2856

.

doi:10.1200/JCO.19.00640

.

13.

Muñoz-González

JI

,

Álvarez-Twose

I

,

Jara-Acevedo

M

, et al.

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

.

Lancet Haematol

.

2021

;

8

(

3

):

e194

-

e204

.

doi:10.1016/S2352-3026(20)30400-2

.

14.

Álvarez-Twose

I

,

Jara-Acevedo

M

,

Morgado

JM

, et al.

Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis

.

J Allergy Clin Immunol

.

2016

;

137

(

1

):

168

-

178.e1

.

doi:10.1016/j.jaci.2015.05.008

.

15.

Valent

P

,

Hartmann

K

,

Schwaab

J

, et al.

Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice

.

J Allergy Clin Immunol Pract

.

2022

;

10

(

8

):

1999

-

2012.e6

.

doi:10.1016/j.jaip.2022.03.007

.

16.

Valent

P

,

Akin

C

,

Escribano

L

, et al.

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

.

Eur J Clin Invest

.

2007

;

37

(

6

):

435

-

453

.

doi:10.1111/j.1365-2362.2007.01807.x

.

17.

Escribano

L

,

Akin

C

,

Castells

M

,

Orfao

A

,

Metcalfe

DD

.

Mastocytosis: current concepts in diagnosis and treatment

.

Ann Hematol

.

2002

;

81

(

12

):

677

-

690

.

doi:10.1007/s00277-002-0575-z

.

18.

Arock

M

,

Valent

P.

Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives

.

Expert Rev Hematol

.

2010

;

3

(

4

):

497

-

516

.

doi:10.1586/ehm.10.42

.

19.

Kettelhut

BV

,

Berkebile

C

,

Bradley

D

,

Metcalfe

DD

.

A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis

.

J Allergy Clin Immunol

.

1989

;

83

(

5

):

866

-

870

.

doi:10.1016/0091-6749(89)90097-3

.

20.

Horan

RF

,

Sheffer

AL

,

Austen

KF

.

Cromlyn sodium in the management of systolic mastocytosis

.

J Allergy Clin Immunol

.

1990

;

85

(

5

):

825

-

855

.

doi:10.1016/0091-6749(90)90067-e

.

21.

Tolar

J

,

Tope

WD

,

Neglia

JP

.

Leukotriene-receptor inhibition for the treatment of systemic mastocytosis

.

N Engl J Med

.

2004

;

350

(

7

):

735

-

736

.

doi:10.1056/NEJM200402123500723

.

22.

Butterfield

JH

.

Survey of aspirin administration in systemic mastocytosis

.

Prostaglandins Other Lipid Mediat

.

2009

;

88

(

3-4

):

122

-

124

.

doi:10.1016/j.prostaglandins.2009.01.001

.

23.

Bonadonna

P

,

Zanotti

R

,

Caruso

B

, et al.

Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and hymenoptera allergy

.

J Allergy Clin Immunol

.

2008

;

121

(

1

):

256

-

257

.

doi:10.1016/j.jaci.2007.10.014

.

24.

Bonadonna

P

,

Gonzalez-de-Olano

D

,

Zanotti

R

, et al.

Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations

.

J Allergy Clin Immunol Pract

.

2013

;

1

(

5

):

474

-

478

.

doi:10.1016/j.jaip.2013.06.014

.

25.

Broesby-Olsen

S

,

Vestergaard

H

,

Mortz

CG

, et al;

Mastocytosis Centre Odense University Hospital (MastOUH)

.

Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations

.

Allergy

.

2018

;

73

(

1

):

230

-

238

.

doi:10.1111/all.13237

.

26.

Jendoubi

F

,

Gaudenzio

N

,

Gallini

A

,

Negretto

M

,

Paul

C

,

Bulai Livideanu

C.

Omalizumab in the treatment of adult patients with mastocytosis: a systematic review

.

Clin Exp Allergy

.

2020

;

50

(

6

):

654

-

661

.

doi:10.1111/cea.13592

.

27.

Gülsen

A

,

Ruëff

F

,

Jappe

U.

Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis

.

Allergol Select

.

2021

;

5

:

128

-

132

.

doi:10.5414/ALX02196E

.

28.

Kluin-Nelemans

HC

,

Oldhoff

JM

,

Van Doormaal

JJ

, et al.

Cladribine therapy for systemic mastocytosis

.

Blood

.

2003

;

102

(

13

):

4270

-

4276

.

doi:10.1182/blood-2003-05-1699

.

29.

Barete

S

,

Lortholary

O

,

Damaj

G

, et al.

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis

.

Blood

.

2015

;

126

(

8

):

1009

-

1016

; quiz 1050.

doi:10.1182/blood-2014-12-614743

.

30.

Gotlib

J

,

Castells

MD

,

Oude Elberink

H

, et al.

Avapritinib versus placebo in indolent systemic mastocytosis

.

NEJM Evidence

.

2023

;

2

(

6

).

doi:10.1056/EVIDoa2200339

.

31.

Alvarez-Twose

I

,

González

P

,

Morgado

JM

, et al.

Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis

.

J Clin Oncol

.

2012

;

30

(

12

):

e126

-

e129

.

doi:10.1200/JCO.2011.38.9973

.

32.

Alvarez-Twose

I

,

Matito

A

,

Morgado

JM

, et al.

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

.

Oncotarget

.

2017

;

8

(

40

):

68950

-

68963

.

doi:10.18632/oncotarget.10711

.

33.

Gotlib

J

,

Kluin-Nelemans

HC

,

George

TI

, et al.

Efficacy and safety of midostaurin in advanced systemic mastocytosis

.

N Engl J Med

.

2016

;

374

(

26

):

2530

-

2541

.

doi:10.1056/NEJMoa1513098

.

34.

Reiter

A

,

Kluin-Nelemans

HC

,

George

T

, et al.

Pooled survival analysis of midostaurin clinical study data (D2201+A2213) in patients with advanced systemic mastocytosis compared with historical controls

.

Haematologica

.

2017

;

102

:

321

-

322

. Accessed

31

August

2017

.

35.

Gotlib

J

,

Reiter

A

,

Radia

DH

, et al.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

.

Nat Med

.

2021

;

27

(

12

):

2192

-

2199

.

doi:10.1038/s41591-021-01539-8

.

36.

DeAngelo

DJ

,

Radia

DH

,

George

TI

, et al.

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

.

Nat Med

.

2021

;

27

(

12

):

2183

-

2191

.

doi:10.1038/s41591-021-01538-9

.

37.

Deininger

MW

,

DeAngelo

DJ

,

Radia

DH

, et al.

Effective control of advanced systemic mastocytosis with avapritinib: mutational analysis from EXPLORER clinical study

.

Blood

.

2021

;

138

(

suppl 1

):

318

.

doi:10.1182/blood-2021-150872

.

38.

Reiter

A

,

Gotlib

J

,

Álvarez-Twose

I

, et al.

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

.

Leukemia

.

2022

;

36

(

8

):

2108

-

2120

.

doi:10.1038/s41375-022-01615-z

.

39.

DeAngelo

DJ

,

Pullarkat

VA

,

Piris-Villaespesa

M

, et al.

Preliminary safety and efficacy from Apex, a phase 2 international study of bezuclastinib (CGT9486), a novel, highly selective, potent KIT D816V tyrosine kinase inhibitor, in adults with advanced systemic mastocytosis (AdvSM)

.

Blood

.

2022

;

140

(

suppl 1

):

1512

-

1513

.

doi:10.1182/blood-2022-156311

.

40.

Ustun

C

,

Reiter

A

,

Scott

BL

, et al.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

.

J Clin Oncol

.

2014

;

32

(

29

):

3264

-

3274

.

doi:10.1200/JCO.2014.55.2018

.

41.

Gotlib

J

,

Gerds

AT

,

Bose

PJ

, et al.

Systemic Mastocytosis, Version2.2019, NCCN Clinical Practice Guidelines in Oncology

.

J Natl Compr Canc Netw

.

2018

;

16

(

12

):

1500

-

1537

.

doi:10.6004/jnccn.2018.0088

.

42.

Sriskandarajah

P

,

McLornan

DP

,

Oni

C

, et al.

Advanced systemic mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant

.

Curr Res Transl Med

.

2023

;

71

(

3

):

103398

.

doi:10.1016/j.retram.2023.103398

.

43.

Gotlib

J

,

Schwaab

J

,

Shomali

W

, et al.

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis

.

J Allergy Clin Immunol Pract

.

2022

;

10

(

8

):

2025

-

2038.e1

.

doi:10.1016/j.jaip.2022.05.034

.